Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218361 | 0.80 | PTGS1 (0.56) | ALDH1A1HTTSMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL5214126 | 0.79 | EPHX1 (0.57) | ALDH1A1HTTSMN1; SMN2HRH3FAAH | |
| SCHEMBL5214115 | 0.79 | EPHX1 (0.57) | ALDH1A1HTTSMN1; SMN2HRH3FAAH | |
| SCHEMBL16811749 | 0.78 | APP (0.46) | APPALDH1A1PTGS2PTGS1CYP2C9 | |
| SCHEMBL5216265 | 0.77 | APP (0.45) | APPPTGS2PTGS1CYP2C9LMNA | |
| SCHEMBL9077712 | 0.76 | APP (0.44) | APPALDH1A1HTTPTGS2PTGS1 | |
| SCHEMBL10399805 | 0.76 | PTGS2 (0.58) | APPPTGS2PTGS1CYP2C9LMNA | |
| SCHEMBL6349692 | 0.75 | APP (0.58) | APPCYP2C9LMNANFKB1PMP22 | |
| SCHEMBL9792793 | 0.74 | APP (0.46) | APPALDH1A1PTGS2PTGS1CYP2C9 | |
| SCHEMBL9792900 | 0.74 | PTGS2 (0.44) | APPPTGS2PTGS1CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276732-B1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | DOMPE PHA R MA SPA RES & MFG (IT) | 2007-09-26 | — | — | EP | disclosed |
| US-7217707-B2 | Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation | DOMPE S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | MMP8, CXCL8, HCAR2 | APP 2281/4885ALDH1A1 391/4885HTT 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.